Investigation of the Chemical Stability of Lenalidomide in Methanol/Ethanol Solvents Using RP-HPLC-UV and LC-MS
DOI:
https://doi.org/10.35516/jjps.v15i3.406Keywords:
Lenalidomide, Degradants, RP-HPLC, Mass spectrometryAbstract
Lenalidomide is a heterocyclic drug used for the treatment of Myelodysplastic syndrome. The current research focuses on the structural elucidation of new degradants that are formed unexpectedly upon storage of lenalidomide in methanol, followed by proposing their corresponding formation mechanism. The proposed structures of the degradants are relatively stable in which two tetrahedral intermediates are resulted from nucleophilic addition of methanol to the carbon of the carbonyl group of imide ring. Methanol molecules, as a solvent, may contribute in stabilizing the intermediate via hydrogen bond formation with it. These degradants were found abundant in lenalidomide/ methanol solution. Hence, the toxicological evaluation of them is crucial.
References
(1) Giagounidis, A. A. N.; Germing, U.; Aul, C. Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies. Clin. Cancer Res. 2006, 12 (1), 5–10.
(2) Naing, A.; Sokol, L.; List, A. F. Developmental Therapeutics for Myelodysplastic Syndromes. J. Natl. Compr. Cancer Netw. 2006, 4 (1), 78–82.
(3) Sanchorawala, V.; Wright, D. G.; Rosenzweig, M.; Finn, K. T.; Fennessey, S.; Zeldis, J. B.; Skinner, M.; Seldin, D. C. Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Results of a Phase 2 Trial. Blood 2007, 109 (2), 492–496.
(4) Alzoman, N. Z. A Validated Stability-Indicating and Stereoselective HPLC Method for the Determination of Lenalidomide Enantiomers in Bulk Form and Capsules. J. Chromatogr. Sci. 2016, 54 (5), 730–735.
(5) Bharti, A.; Jeyaseelan, C. Quantification of Potential Impurities Present in Testosterone Undecanoate Active Pharmaceutical Ingredient by Stability Indicating HPLC Method Using UV Detector. Jordan Journal of Pharmaceutical Sciences. 2019, 12 (1).
(6) de Oliveira Melo, S. R.; Homem-de-Mello, M.; Silveira, D.; Simeoni, L. A. Advice on Degradation Products in Pharmaceuticals: A Toxicological Evaluation. PDA J. Pharm. Sci. Technol. 2014, 68 (3), 221–238.
(7) Dhangar, K. R.; Jagtap, R. B.; Surana, S. J.; Shirkhedkar, A. A. Impurity Profiling of Drugs towards Safety and Efficacy: Theory and Practice. J. Chil. Chem. Soc. 2017, 62 (2), 3543–3557.
(8) Pan, C.; Liu, F.; Motto, M. Identification of Pharmaceutical Impurities in Formulated Dosage Forms. J. Pharm. Sci. 2011, 100 (4), 1228–1259.
(9) Bari, S. B.; Kadam, B. R.; Jaiswal, Y. S.; Shirkhedkar, A. A. Impurity Profile: Significance in Active Pharmaceutical Ingredient. Eurasian J. Anal. Chem. 2007, 2 (1), 32–53.
(10) Wada, M.; Alkhalil, S. M.; Nakashima, K. Current HPLC Methods for Determination of Medicaments in Formulations and Biological Samples. Jordan Journal of Pharmaceutical Sciences 2008, 1 (1), 1–27.
(11) Reddy, L. M.; Reddy, K. J.; Reddy, L. B.; Reddy, P. R. Development of a Rapid and Sensitive HPLC Assay Method for Lenalidomide Capsules and Its Related Substances. E-Journal Chem. 2012, 9 (3), 1165–1174.
(12) Al-Qudah, E.; Arar, S.; Sweidan, K. Forced Degradation Studies of Vildagliptin Raw Material Alone and in the Presence of Excipients Using HPLC-UV Analysis. J. Excipients Food Chem. 2020, 11 (2), 29–41.
(13) Arar, S.; Al-Qudah, E.; Alzweiri, M.; Sweidan, K. New Forced Degradation Products of Vildagliptin: Identification and Structural Elucidation Using LC-MS, with Proposed Formation Mechanisms. J. Liq. Chromatogr. Relat. Technol. 2020, 43 (15–16), 633–644.
(14) Arar, S.; Sweidan, K.; Qasem, S. Identification and Characterization of the Degradation Products of Prasugrel Hydrochloride Tablets Using LC-MS Technique. J. Liq. Chromatogr. Relat. Technol. 2018, 41 (1), 14–23.
(15) Sweidan, K.; Elayan, M.; Sabbah, D.; Idrees, G.; Arafat, T. Study of Forced Degradation Behavior of Amisulpride by LC-MS and NMR and Development of a Stability-Indicating Method. Curr. Pharm. Anal. 2018, 14 (2), 157–165.
(16) Shu, C.; Zeng, T.; Gao, S.; Xia, T.; Huang, L.; Zhang, F.; Chen, W. LC–MS/MS Method for Simultaneous Determination of Thalidomide, Lenalidomide, Cyclophosphamide, Bortezomib, Dexamethasone and Adriamycin in Serum of Multiple Myeloma Patients. J. Chromatogr. B 2016, 1028, 111–119.
(17) Prasad, S. S.; Mohan, G. V. K.; Babu, A. N. Development and Validation of Stability-Indicating RP-HPLC Method for the Estimation of Lenalidomide and Its Impurities in Oral Solid Dosage Form. Orient. J. Chem. 2019, 35 (1), 140.
(18) Venkateshwarlu, P.; Patel, M. M. Method Development and Validation of Degradation Studies of Lenalidomide by RP-HPLC. Res. J. Pharm. Technol. 2021, 14 (8), 4281–4286.
(19) Siadati, S. A.; Payab, M.; Beheshti, A. Development of a Reversed-Phase HPLC Method for Determination of Related Impurities of Lenalidomide. Chem. Rev. Lett. 2020, 3 (2), 61–64.
(20) Raghu, N. S.; Reddy, Y. R.; Naresh, V.; Suryanarayana Rao, V.; Ravindranath, L. K. Degradation Studies of Highly Potent and Life Threatening Human Birth Defect Drug—Lenalidomide by HPLC and LC-MS. J. Liq. Chromatogr. Relat. Technol. 2010, 33 (5), 654–679.
(21) Piou, T.; Rovis, T. Rhodium-Catalysed Syn-Carboamination of Alkenes via a Transient Directing Group. Nature 2015, 527 (7576), 86–90.
(22) Chen, W.-H.; Gao, X. J.; Gao, X. Methanol-Assisted Phthalimide Ring Opening: Concerted or Stepwise Mechanism? J. Phys. Chem. A 2018, 122 (12), 3115–3119.
